Molecular targeting of acid ceramidase in glioblastoma: A review of its role, potential treatment, and challenges
Publication Type
Original research
Authors
Fulltext
Download

Glioblastoma is the most common, malignant primary tumor of the central nervous system. The average prognosis for life expectancy after diagnosis, with the triad of surgery, chemotherapy, and radiation therapy, is less than 1.5 years. Chemotherapy treatment is mostly limited to temozolomide. In this paper, the authors review an emerging, novel drug called acid ceramidase, which targets glioblastoma. Its role in cancer treatment in general, and more specifically, in the treatment of glioblastoma, are discussed. In addition, the authors provide insights on acid ceramidase as a potential druggable target for glioblastoma. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.

Journal
Title
Pharmaceutics
Publisher
MDPI AG
Publisher Country
Eswatini
Indexing
Scopus
Impact Factor
None
Publication Type
Both (Printed and Online)
Volume
10
Year
2018
Pages
--